Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 68180-604

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 68180-604). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

E53b48c7 C480 4860 A258 01bf7e00bb1d 01

Chemical structure diagram of Desvenlafaxine Succinate showing molecular components including aromatic rings, hydroxyl, amine groups, and succinate with water of hydration.*

FDA Label Image

E53b48c7 C480 4860 A258 01bf7e00bb1d 02

A line chart titled 'Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5)' showing two curves comparing relapse rates over about 200 days. The solid line represents Desvenlafaxine extended-release tablets 50 mg, and the dashed line represents placebo. The vertical axis shows estimated proportion of patients with relapse (%) up to 50%, and the horizontal axis shows time to relapse in days from randomization up to 200 days.*

FDA Label Image

E53b48c7 C480 4860 A258 01bf7e00bb1d 03

Kaplan-Meier survival curve showing the estimated proportion of patients with relapse over time (days from randomization) comparing Desvenlafaxine extended-release tablets versus placebo. The solid line represents Desvenlafaxine, and the dashed line represents placebo, with relapse percentages on the vertical axis and time in days on the horizontal axis up to about 180 days.*

FDA Label Image

E53b48c7 C480 4860 A258 01bf7e00bb1d 04

Label for Desvenlafaxine Extended-Release Tablets 25 mg by Lupin Pharmaceuticals, Inc. The label shows an NDC of 68180-604-06 and indicates a unit of use containing 30 film-coated, extended-release tablets. It includes storage instructions, a barcode, and manufacturer information for Lupin Limited in India and Lupin Pharmaceuticals in the United States.*

FDA Label Image

E53b48c7 C480 4860 A258 01bf7e00bb1d 05

Label for Desvenlafaxine Extended-Release Tablets 50 mg, film-coated, extended-release oral tablets. The label indicates a 30-tablet unit of use and is manufactured for Lupin Pharmaceuticals, Inc. The label includes an NDC number, storage instructions, and a QR code for the medication guide.*

FDA Label Image

E53b48c7 C480 4860 A258 01bf7e00bb1d 06

Desvenlafaxine Succinate Extended-Release Tablets 100 mg film-coated tablet label from Lupin Pharmaceuticals, Inc. The label specifies the unit of use as 30 tablets and includes storage instructions, a barcode, manufacturing information, and a QR code linking to the medication guide.*

FDA Label Image

E53b48c7 C480 4860 A258 01bf7e00bb1d 07

A pharmacokinetic impact figure displaying the geometric mean ratio and 90% confidence intervals of Cmax and AUC for Desvenlafaxine in populations with varying renal and hepatic impairment, and different demographic groups categorized by gender and age. The chart assesses changes relative to a reference group for renal impairment (mild, moderate, severe, ESRD), hepatic impairment (mild, moderate, severe), and population descriptions (females, ages 65-75 years, and >75 years).*

FDA Label Image

E53b48c7 C480 4860 A258 01bf7e00bb1d 08

A chart illustrating the effect of CYP3A4 inhibitor ketoconazole on desvenlafaxine pharmacokinetics, showing geometric mean ratios with 90% confidence intervals for Cmax and AUC relative to reference. The Cmax ratio is approximately 1.08, and the AUC ratio is approximately 1.43, indicating changes in drug exposure when administered with ketoconazole.*

FDA Label Image

E53b48c7 C480 4860 A258 01bf7e00bb1d 09

A forest plot titled 'Effects of Desvenlafaxine on Pharmacokinetics of Other Drugs' showing geometric mean ratios and 90% confidence intervals for Cmax and AUC of various interacting drugs (Desipramine, Midazolam, Tamoxifen, Aripiprazole) at different Desvenlafaxine doses. The chart compares pharmacokinetic changes relative to reference values for CYP2D6, CYP3A4, and combined CYP2D6 & CYP3A4 substrates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.